Report of Foreign Issuer (6-k)
March 15 2017 - 6:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13A-16
OR
15D-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Dated March 15, 2017
Commission File Number
001-35428
P
RIMA
B
IO
M
ED
L
TD
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
Level 12, 95 Pitt Street
Sydney, 2000 New South Wales, Australia
(Address of principal executive office)
Indicate by
check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by
Regulation
S-T
Rule 101(b) (1): ☐
Indicate by check mark if the registrant is
submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b) (7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Dated: March 15, 2017
|
|
|
|
|
Prima BioMed Ltd
|
|
|
By:
|
|
/s/ Marc Voigt
|
|
|
Name:
|
|
Marc Voigt
|
|
|
Title:
|
|
Chief Executive Officer
|
2
EXHIBIT INDEX
|
|
|
Exhibit
|
|
Description of Exhibit
|
|
|
99.1
|
|
PRIMA BIOMED COMPLETES RECRUITMENT FOR SECOND PATIENT COHORT IN MELANOMA TRIAL AND WILL PRESENT AT ICI CONFERENCE IN
BOSTON
|
3
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Sep 2023 to Sep 2024